Michael A Caligiuri

List of Publications by Citations

131 papers	13,762 citations	50 h-index	117 g-index
139 ext. papers	16,128 ext. citations	10.4 avg, IF	6.67 L-index

#	Paper	IF	Citations
131	The biology of human natural killer-cell subsets. *Trends in Immunology*, **2001**, 22, 633-40	14.4	2075
130	Human natural killer cells. *Blood*, **2008**, 112, 461-9	2.2	1261
129	Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. *Blood*, **2001**, 97, 3146-51	2.2	1023
128	Interleukin 15: biology and relevance to human disease. *Blood*, **2001**, 97, 14-32	2.2	758
127	Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection. *Journal of Immunology*, **2002**, 169, 4279-87	5.3	494
126	Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. *Blood*, **2002**, 100, 1935-47	2.2	405
125	Obesity, Inflammation, and Cancer. *Annual Review of Pathology: Mechanisms of Disease*, **2016**, 11, 421-49	34	381
124	Human natural killer cell development. *Immunological Reviews*, **2006**, 214, 56-72	11.3	362
123	In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. *Blood*, **2002**, 100, 3633-8	2.2	341
122	Evidence for discrete stages of human natural killer cell differentiation in vivo. *Journal of Experimental Medicine*, **2006**, 203, 1033-43	16.6	327
121	Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. *Blood*, **2009**, 114, 2667-77	2.2	305
120	The Broad Spectrum of Human Natural Killer Cell Diversity. *Immunity*, **2017**, 47, 820-833	32.3	302
119	Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. *Journal of Experimental Medicine*, **2001**, 193, 219-31	16.6	292
118	A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells. *Immunity*, **2005**, 22, 295-304	32.3	288
117	Interleukin-2, interleukin-15, and their roles in human natural killer cells. *Advances in Immunology*, **2005**, 86, 209-39	5.6	228
116	Location and cellular stages of natural killer cell development. *Trends in Immunology*, **2013**, 34, 573-82	14.4	222
115	Ibrutinib treatment improves T cell number and function in CLL patients. *Journal of Clinical Investigation*, **2017**, 127, 3052-3064	15.9	197

114	A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. *Blood*, **2012**, 120, 4324-33	2.2	193
113	CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells. *Scientific Reports*, **2015**, 5, 11483	4.9	189
112	Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells. *Immunity*, **2006**, 24, 575-90	32.3	189
111	CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets. *Blood*, **2010**, 115, 274-81	2.2	180
110	Interleukin-1beta selectively expands and sustains interleukin-22+ immature human natural killer cells in secondary lymphoid tissue. *Immunity*, **2010**, 32, 803-14	32.3	167
109	TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. *Journal of Immunology*, **2008**, 181, 3784-92	5.3	158
108	NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. *Nature Medicine*, **2012**, 18, 1827-34	50.5	142
107	Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion. *Nature*, **2019**, 572, 254-259	50.4	131
106	Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. *European Journal of Immunology*, **2001**, 31, 3016-25	6.1	129
105	A Progenitor Cell Expressing Transcription Factor RORγt Generates All Human Innate Lymphoid Cell Subsets. *Immunity*, **2016**, 44, 1140-50	32.3	125
104	Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment. *Cancer Research*, **2016**, 76, 2125-36	10.1	121
103	Molecular pathways: interleukin-15 signaling in health and in cancer. *Clinical Cancer Research*, **2014**, 20, 2044-50	12.9	118
102	Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation. *Cancer Cell*, **2012**, 22, 645-55	24.3	115
101	Stage 3 immature human natural killer cells found in secondary lymphoid tissue constitutively and selectively express the TH 17 cytokine interleukin-22. *Blood*, **2009**, 113, 4008-10	2.2	106
100	Transcription factor Foxo1 is a negative regulator of natural killer cell maturation and function. *Immunity*, **2015**, 42, 457-70	32.3	102
99	The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector. *Cancer Discovery*, **2019**, 9, 1422-1437	24.4	90
98	Human natural killer cell development in secondary lymphoid tissues. *Seminars in Immunology*, **2014** , 26, 132-7	10.7	85
97	Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses. *Cell Reports Medicine*, **2021**, 2, 100189	18	80

96	CSIG-23. NOTCH ACTIVATION INDUCED BY HSV-1 ENCODED miRNA-H16 SENSITIZES oHSV-TREATED TUMORS TO NOTCH INHIBITOR. *Neuro-Oncology*, **2019**, 21, vi49-vi49	1	78
95	Modeling Human Natural Killer Cell Development in the Era of Innate Lymphoid Cells. *Frontiers in Immunology*, **2017**, 8, 360	8.4	70
94	NKp80 Defines a Critical Step during Human Natural Killer Cell Development. *Cell Reports*, **2016**, 16, 379-396	15.0	68
93	The transcription Factor AHR prevents the differentiation of a stage 3 innate lymphoid cell subset to natural killer cells. *Cell Reports*, **2014**, 8, 150-62	10.6	65
92	Evidence for a stepwise program of extrathymic T cell development within the human tonsil. *Journal of Clinical Investigation*, **2012**, 122, 1403-15	15.9	65
91	Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts. *Blood*, **2016**, 127, 2879-89	2.2	63
90	Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias. *Blood*, **2012**, 120, 1130-6	2.2	62
89	TGF Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response. *Cancer Research*, **2015**, 75, 5273-82	10.1	61
88	Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model. *Molecular Cancer Therapeutics*, **2017**, 16, 312-322	6.1	59
87	CD56 Expression Marks Human Group 2 Innate Lymphoid Cell Divergence from a Shared NK Cell and Group 3 Innate Lymphoid Cell Developmental Pathway. *Immunity*, **2018**, 49, 464-476.e4	32.3	57
86	Biallelic mutations in IRF8 impair human NK cell maturation and function. *Journal of Clinical Investigation*, **2017**, 127, 306-320	15.9	53
85	Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma. *Cancer Discovery*, **2016**, 6, 986-1005	24.4	52
84	Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy. *Journal of Hematology and Oncology*, **2020**, 13, 168	22.4	51
83	NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human. *Journal of Clinical Investigation*, **2011**, 121, 1456-70	15.9	51
82	A review of the association between interleukin-10 and human B-cell malignancies. *Cancer Immunology, Immunotherapy*, **1998**, 46, 239-44	7.4	50
81	A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma. *Cancer Immunology Research*, **2018**, 6, 776-787	12.5	50
80	The Axl/Gas6 pathway is required for optimal cytokine signaling during human natural killer cell development. *Blood*, **2009**, 113, 2470-7	2.2	49
79	IL-18 Drives ILC3 Proliferation and Promotes IL-22 Production via NF- B. *Journal of Immunology*, **2017**, 199, 2333-2342	5.3	46

78	Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function. *Blood*, **2018**, 132, 1792-1804	2.2	46
77	Restriction landmark genome scanning for aberrant methylation in primary refractory and relapsed acute myeloid leukemia; involvement of the WIT-1 gene. *Oncogene*, **1999**, 18, 3159-65	9.2	45
76	Molecular and clinical advances in core binding factor primary acute myeloid leukemia: a paradigm for translational research in malignant hematology. *Cancer Investigation*, **2000**, 18, 768-80	2.1	43
75	MicroRNA-29b mediates altered innate immune development in acute leukemia. *Journal of Clinical Investigation*, **2016**, 126, 4404-4416	15.9	42
74	The IL-15-AKT-XBP1s signaling pathway contributes to effector functions and survival in human NK cells. *Nature Immunology*, **2019**, 20, 10-17	19.1	42
73	Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cells. *Blood*, **2014**, 124, 1127-35	2.2	41
72	SMAD4 promotes TGF-□independent NK cell homeostasis and maturation and antitumor immunity. *Journal of Clinical Investigation*, **2018**, 128, 5123-5136	15.9	41
71	In vivo role of Flt3 ligand and dendritic cells in NK cell homeostasis. *Journal of Immunology*, **2010**, 184, 2769-75	5.3	40
70	Complex role of NK cells in regulation of oncolytic virus-bortezomib therapy. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 4927-4932	11.5	37
69	An oncolytic herpesvirus expressing E-cadherin improves survival in mouse models of glioblastoma. *Nature Biotechnology*, **2018**,	44.5	36
68	The natural product phyllanthusmin C enhances IFN-□production by human NK cells through upregulation of TLR-mediated NF-B signaling. *Journal of Immunology*, **2014**, 193, 2994-3002	5.3	35
67	Environmental and Genetic Activation of Hypothalamic BDNF Modulates T-cell Immunity to Exert an Anticancer Phenotype. *Cancer Immunology Research*, **2016**, 4, 488-497	12.5	35
66	Cellular pathways in the development of human and murine innate lymphoid cells. *Current Opinion in Immunology*, **2019**, 56, 100-106	7.8	30
65	PTEN is a negative regulator of NK cell cytolytic function. *Journal of Immunology*, **2015**, 194, 1832-40	5.3	28
64	Promoter-Specific Hypomethylation Is Associated with Overexpression of PLS3, GATA6, and TWIST1 in the Sezary Syndrome. *Journal of Investigative Dermatology*, **2015**, 135, 2084-2092	4.3	27
63	Ontogeny and expansion of human natural killer cells: clinical implications. *International Reviews of Immunology*, **2001**, 20, 503-34	4.6	26
62	The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells. *Journal of Immunology*, **2015**, 195, 1995-2005	5.3	24
61	Immunotherapeutic approaches for hematologic malignancies. *Hematology American Society of Hematology Education Program*, **2004**, 2004, 337-53	3.1	24

60	Enriched environment regulates thymocyte development and alleviates experimental autoimmune encephalomyelitis in mice. *Brain, Behavior, and Immunity*, **2019**, 75, 137-148	16.6	23
59	BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection-Implications for Oncolytic Viral Therapy. *Clinical Cancer Research*, **2017**, 23, 1809-1819	12.9	20
58	Adipocytes: A Novel Target for IL-15/IL-15R□Cancer Gene Therapy. *Molecular Therapy*, **2019**, 27, 922-932	11.7	19
57	The Fc Domain of Immunoglobulin Is Sufficient to Bridge NK Cells with Virally Infected Cells. *Immunity*, **2017**, 47, 159-170.e10	32.3	19
56	An Oncolytic Virus Expressing IL15/IL15R□Combined with Off-the-Shelf EGFR-CAR NK Cells Targets Glioblastoma. *Cancer Research*, **2021**, 81, 3635-3648	10.1	18
55	The RNA m6A reader YTHDF2 controls NK cell antitumor and antiviral immunity. *Journal of Experimental Medicine*, **2021**, 218,	16.6	18
54	Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development. *Journal of Immunology*, **2018**, 200, 565-572	5.3	18
53	A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma. *Clinical Cancer Research*, **2019**, 25, 4955-4965	12.9	16
52	Combined loss of function of two different loci of miR-15/16 drives the pathogenesis of acute myeloid leukemia. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 12332-12340	11.5	16
51	Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and Dexamethasone. *Clinical Cancer Research*, **2018**, 24, 3273-3281	12.9	16
50	A novel mouse model for the aggressive variant of NK cell and T cell large granular lymphocyte leukemia. *Leukemia Research*, **2010**, 34, 203-9	2.7	15
49	The Epstein-Barr Virus Lytic Protein BZLF1 as a Candidate Target Antigen for Vaccine Development. *Cancer Immunology Research*, **2015**, 3, 787-94	12.5	14
48	Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with an endemic human CoV **2020**,		14
47	Oncolytic HSV-Infected Glioma Cells Activate NOTCH in Adjacent Tumor Cells Sensitizing Tumors to Gamma Secretase Inhibition. *Clinical Cancer Research*, **2020**, 26, 2381-2392	12.9	13
46	Molecular Basis for the Recognition of Herpes Simplex Virus Type 1 Infection by Human Natural Killer Cells. *Frontiers in Immunology*, **2018**, 9, 183	8.4	12
45	CSF1R inhibitor PLX5622 and environmental enrichment additively improve metabolic outcomes in middle-aged female mice. *Aging*, **2020**, 12, 2101-2122	5.6	12
44	A novel regimen for relapsed/refractory adult acute myeloid leukemia using a partial tandem duplication targeted therapy: results of phase 1 study NCI 8485. *Haematologica*, **2018**, 103, 982-987	6.6	11
43	Patient Enrichment for Precision-Based Cancer Clinical Trials: Using Prospective Cohort Surveillance as an Approach to Improve Clinical Trials. *Clinical Pharmacology and Therapeutics*, **2018**, 104, 23-26	6.1	9

42	The K18-hACE2 Transgenic Mouse Model Recapitulates Non-Severe and Severe COVID-19 in Response to Infectious Dose of SARS-CoV-2 Virus. *Journal of Virology*, **2021**, JVI0096421	6.6	8
41	Notch Regulates Innate Lymphoid Cell Plasticity during Human NK Cell Development. *Journal of Immunology*, **2020**, 205, 2679-2693	5.3	8
40	Rapid Column-Free Enrichment of Mononuclear Cells from Solid Tissues. *Scientific Reports*, **2015**, 5, 12490	4.9	7
39	Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia. *Blood*, **2021**, 138, 1465-1480	2.2	7
38	An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma. *Nature Communications*, **2021**, 12, 5908	17.4	6
37	Increased Levels of Plasma Epstein Barr Virus DNA Identify a Poor-Risk Subset of Patients With Advanced Stage Cutaneous T-Cell Lymphoma. *Clinical Lymphoma, Myeloma and Leukemia*, **2016**, 16 Suppl, S181-S190.e4	2	5
36	Off-the-shelf PSCA-directed chimeric antigen receptor natural killer cell therapy to treat pancreatic cancer.. *Gastroenterology*, **2022**,	13.3	5
35	Enriched environment enhances NK cell maturation through hypothalamic BDNF in male mice. *European Journal of Immunology*, **2021**, 51, 557-566	6.1	5
34	A Phase II Study of the TNF-Inhibitor Etanercept and Thrice Weekly Rituximab in Relapsed CLL/SLL: Clinical Activity in the Absence of Del(17p13) Genomic Abnormalities.. *Blood*, **2006**, 108, 2841-2841	2.2	4
33	CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma. *JCI Insight*, **2021**, 6,	9.9	4
32	NK Cells Contribute Significantly to the Innate Immune Effector Role of CD37-Specific SMIP in CLL and NHL.. *Blood*, **2006**, 108, 135-135	2.2	3
31	Select High Risk Genetic Features Predict Earlier Progression Following Chemoimmunotherapy with Fludarabine and Rituximab in Chronic Lymphocytic Leukemia (CLL): Preliminary Justification for Risk-Adapted Therapy.. *Blood*, **2004**, 104, 476-476	2.2	3
30	Oncolytic HSV Vectors and Anti-Tumor Immunity. *Current Issues in Molecular Biology*, **2021**, 41, 381-468	2.9	3
29	Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2 / neu-positive breast cancer cells **2001**, 31, 3016		3
28	Off-the-shelf CAR natural killer cells secreting IL-15 target spike in treating COVID-19.. *Nature Communications*, **2022**, 13, 2576	17.4	3
27	Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma.. *Blood Cancer Discovery*, **2022**, 3, 154-169	7	2
26	Elucidation of the Molecular Mechanisms by Which Inflammatory and Anti-Inflammatory Monokines Regulate Interferon (IFN)- Production.. *Blood*, **2004**, 104, 111-111	2.2	2
25	Targeting Fc Receptor-Mediated Effects and the "Don't Eat Me" Signal with an Oncolytic Virus Expressing an Anti-CD47 Antibody to Treat Metastatic Ovarian Cancer. *Clinical Cancer Research*, **2021**,	12.9	2

24	Enhancing Effects of Environmental Enrichment on the Functions of Natural Killer Cells in Mice. *Frontiers in Immunology*, **2021**, 12, 695859	8.4	2
23	Unraveling the Role of Innate Lymphoid Cells in AcuteMyeloid Leukemia. *Cancers*, **2021**, 13,	6.6	2
22	Hijacking TYRO3 from Tumor Cells via Trogocytosis Enhances NK-cell Effector Functions and Proliferation. *Cancer Immunology Research*, **2021**, 9, 1229-1241	12.5	2
21	Cbl-b Is Upregulated and Plays a Negative Role in Activated Human NK Cells. *Journal of Immunology* , **2021**, 206, 677-685	5.3	2
20	Amplification of mixed lineage leukemia gene perturbs hematopoiesis and cooperates with partial tandem duplication to induce acute myeloid leukemia. *Haematologica*, **2017**, 102, e300-e304	6.6	1
19	PDGF-D-PDGFR signaling enhances IL-15-mediated human natural killer cell survival.. *Proceedings of the National Academy of Sciences of the United States of America*, **2022**, 119,	11.5	1
18	The Clinical Role of Micrornas (miRs) in Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML): miR-155 Upregulation Independently Identifies High-Risk Patients (Pts). *Blood*, **2012**, 120, 1387-1387	2.2	1
17	A Phase II Study of the TNF- Inhibitor Etanercept and Thrice Weekly Rituximab: Evidence of Clinical Activity in the Absence of del(17p13.1) Genomic Abnormalities.. *Blood*, **2004**, 104, 3469-3469	2.2	1
16	Effective Targeting of Acute Myeloid Leukemia (AML) Harboring the FLT3 ITD Mutation through the Axl/Gas6 Pathway. *Blood*, **2010**, 116, 500-500	2.2	1
15	The RNA m6A reader YTHDF2 controls NK cell anti-tumor and anti-viral immunity		1
14	Improving Goal Concordant Care Among 10 Leading Academic U.S. Cancer Hospitals: A Collaboration of the Alliance of Dedicated Cancer Centers. *Oncologist*, **2021**, 26, 533-536	5.7	1
13	Environmental activation of a hypothalamic BDNF-adipocyte IL-15 axis regulates adipose-natural killer cells. *Brain, Behavior, and Immunity*, **2021**, 95, 477-488	16.6	1
12	Acute Myeloid Leukemia Alters Group 1 Innate Lymphoid Cell Differentiation from a Common Precursor. *Journal of Immunology*, **2021**, 207, 1672-1682	5.3	1
11	A four-stage model for murine natural killer cell development in vivo.. *Journal of Hematology and Oncology*, **2022**, 15, 31	22.4	0
10	Role of Mir-29b in T-Cell Development and in Cutaneous T-Cell Lymphoma Pathogenesis. *Blood*, **2020**, 136, 37-37	2.2	
9	Activated Natural Killer Cells Are Associated with Poor Clinical Prognosis in High-Risk B- and T- Cell Acute Lymphoblastic Leukemia. *Blood*, **2020**, 136, 39-39	2.2	
8	Efficient and Reproducible Retroviral Infection of Primary Human Natural Killer Cells.. *Blood*, **2004**, 104, 1348-1348	2.2	
7	ReSETting PP2A Tumor Suppressor Activity Overcomes BCR/ABL Leukemogenic Potential in Blast Crisis CML.. *Blood*, **2005**, 106, 1992-1992	2.2	

List of Publications

6	FLT3-ITD Activates Cytoplasmic Drosha-Dependent Non-Canonical Mechanisms of Mir-155 Biogenesis in Acute Myeloid Leukemia. *Blood*, **2019**, 134, 2722-2722	2.2
5	The Epstein-Barr Virus Lytic Protein BZLF1 As a Candidate Target Antigen for Vaccine Development. *Blood*, **2014**, 124, 4144-4144	2.2
4	Characterization of An NKp46+ NKT Subset Which Is Susceptible to Malignant Transformation in Vivo.. *Blood*, **2008**, 112, 1546-1546	2.2
3	MLL-PTD Causes Hypomorph Condition of CBF Complex (RUNX1/CBF) and Predisposes the Abnormal Hematopoietic Stem and Progenitor Cells (HSPCs) to Clonal Expansion. *Blood*, **2011**, 118, 2801-2801	2.2
2	Activation of a Mir-181-Targeting HOXA-PBX3 Homeobox Gene Signature Is Associated with Adverse Prognosis of Cytogenetically Abnormal Acute Myeloid Leukemia. *Blood*, **2011**, 118, 236-236	2.2
1	Human Natural Killer (NK) Cells: Differential Expression of Phosphatase and Tensin Homologue Deleted On Chromosome Ten (PTEN) During NK Cell Development Regulates Its Cytolytic Activity Against Leukemic Target Cells. *Blood*, **2012**, 120, 254-254	2.2